NCT03574363View on ClinicalTrials.gov

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

162

Participants

Timeline

Start Date

April 25, 2018

Primary Completion Date

August 5, 2020

Study Completion Date

August 5, 2020

Conditions
Chronic Kidney DiseasesHypertension
Interventions
DRUG

KBP-5074 0.25 mg tablet

Oral administration, QD, 84 days

DRUG

KBP-5074 0.5 mg tablet

Oral administration, QD, 84 days

Trial Locations (2)

27560

Worldwide Clinical Trials, Morrisville

08540

KBP Biosciences USA Inc, Princeton

Sponsors

Lead Sponsor

KBP Biosciences

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

KBP Biosciences

INDUSTRY